MACE Risk After Intracerebral Haemorrhage (ICH): SHARP Research Grant Project Update
We’re pleased to share an update on an ongoing SHARP-funded research project led by Dr. Tom Moullaali from the University of Edinburgh, focused on understanding the risks and predictors of major adverse cardiovascular and cerebrovascular events (MACE) following stroke due to intracerebral haemorrhage (ICH).
This international, individual participant data meta-analysis (IPDMA) aims to identify the absolute risks and key predictors of MACE after stroke in ICH survivors. The study is collecting data from ~200,000 individuals across 26 eligible studies, with the goal of developing a risk prediction model that will guide clinical decisions and improve personalised treatment for those affected by ICH.
Progress to date includes:
Completion of a systematic literature search and data summarisation.
Presentation of results at the 2024 SHARP Annual Meeting.
Development of an analysis protocol
Eight studies, with a combined total of 19,132 participants, have preliminarily agreed to collaborate with the IPDMA.
Looking ahead, the team is focusing on data management strategies and will soon invite collaborators to join the IPDMA.
Future plans include:
Incorporating prediction models into a smartphone app for use in clinical practice.
Enhancing the forthcoming, funded international randomised trial of antiplatelet drugs after ICH (www.ASPIRING.ed.ac.uk) by using the prediction models to investigate variation in treatment effect based on predicted risk of MACE.
We are excited about the potential impact this research will have on improving prevention strategies for ICH survivors, both in Scotland and internationally.
Stay tuned for further updates as this important project progresses!